Literature DB >> 20031556

Determination of paraoxonase 1 status without the use of toxic organophosphate substrates.

Rebecca J Richter1, Gail P Jarvik, Clement E Furlong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 20031556      PMCID： PMC3035628          DOI： 10.1161/CIRCGENETICS.108.811638

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN： 1942-3268


× No keyword cloud information.
  47 in total

1.  The association of the PON1 Q192R polymorphism with complications and outcomes of pregnancy: findings from the British Women's Heart and Health cohort study.

Authors:  Debbie A Lawlor; Tom R Gaunt; Lesley J Hinks; George Davey Smith; Nick Timpson; Ian N M Day; Shah Ebrahim
Journal:  Paediatr Perinat Epidemiol       Date:  2006-05       Impact factor: 3.980

2.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

3.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Authors:  M Aviram; M Rosenblat; C L Bisgaier; R S Newton; S L Primo-Parmo; B N La Du
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

4.  Genetic and environmental determinants of the PON-1 phenotype.

Authors:  M Roest; T M van Himbergen; A B Barendrecht; P H M Peeters; Y T van der Schouw; H A M Voorbij
Journal:  Eur J Clin Invest       Date:  2007-03       Impact factor: 4.686

5.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression.

Authors:  V H Brophy; R L Jampsa; J B Clendenning; L A McKinstry; G P Jarvik; C E Furlong
Journal:  Am J Hum Genet       Date:  2001-05-02       Impact factor: 11.025

6.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Authors:  S L Primo-Parmo; R C Sorenson; J Teiber; B N La Du
Journal:  Genomics       Date:  1996-05-01       Impact factor: 5.736

7.  Expression of human paraoxonase (PON1) during development.

Authors:  Toby B Cole; Rachel L Jampsa; Betsy J Walter; Tara L Arndt; Rebecca J Richter; Diana M Shih; Aaron Tward; Aldons J Lusis; Rhona M Jack; Lucio G Costa; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-06

Review 8.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

Review 9.  Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.

Authors:  Sara P Deakin; Richard W James
Journal:  Clin Sci (Lond)       Date:  2004-11       Impact factor: 6.124

10.  Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857
View more
  42 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

Review 3.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

4.  Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds.

Authors:  Karen L Jansen; Toby B Cole; Sarah S Park; Clement E Furlong; Lucio G Costa
Journal:  Toxicol Appl Pharmacol       Date:  2009-02-09       Impact factor: 4.219

5.  Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression.

Authors:  Toby B Cole; Richard P Beyer; Theo K Bammler; Sarah S Park; Federico M Farin; Lucio G Costa; Clement E Furlong
Journal:  Toxicol Sci       Date:  2011-06-14       Impact factor: 4.849

6.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 7.  Paraoxonase-1 and Early-Life Environmental Exposures.

Authors:  Judit Marsillach; Lucio G Costa; Clement E Furlong
Journal:  Ann Glob Health       Date:  2016 Jan-Feb       Impact factor: 2.462

8.  Household organophosphorus pesticide use and Parkinson's disease.

Authors:  Shilpa Narayan; Zeyan Liew; Kimberly Paul; Pei-Chen Lee; Janet S Sinsheimer; Jeff M Bronstein; Beate Ritz
Journal:  Int J Epidemiol       Date:  2013-09-20       Impact factor: 7.196

9.  In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life.

Authors:  Juliana Brum Moraes; Michael Maes; Chutima Roomruangwong; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; George Anderson; Marta Kubera; Andre F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

Review 10.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.